Complete response after short-term sorafenib treatment in a patient with lymph node metastasis of hepatocellular carcinoma

Case Reports in Oncology

Volumn 5, Issue 2, 2012, Pages 380-384

  Mizukami, Hajime ^a   Kagawa, Tatehiro ^a   Arase, Yoshitaka ^a   Nakahara, Fumio ^a   Tsuruya, Kota ^a   Anzai, Kazuya ^a   Hirose, Shunji ^a   Shiraishi, Koichi ^a   Shomura, Masako ^b   Koizumi, Jun ^a   Tobita, Kosuke ^c   Mine, Tetsuya ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

Author keywords

Complete response; Hand foot skin reaction; Hepatocellular carcinoma; Lymph node; Recurrence; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; INTERFERON; LECTIN; RIBAVIRIN; SORAFENIB;

ADULT; ARTICLE; CANCER SURGERY; CASE REPORT; DRUG ERUPTION; DRUG RESPONSE; DRUG WITHDRAWAL; HAND FOOT SYNDROME; HEPATITIS C; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; LIVER RESECTION; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; RATING SCALE; REMISSION; SHORT COURSE THERAPY; SWELLING; TUMOR VOLUME;

EID: 84866859310     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000341259     Document Type: Article

References (14)

1. Cheng AL, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
2. Llovet JM, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008;359:378-390.
3. Therasse P, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
4. So BJ, et al: Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report. J Hematol Oncol 2008;1:18.
5. Sacco R, et al: Complete response for advanced liver cancer during sorafenib therapy: Case report. BMC Gastroenterol 2011;11:4.
6. Irtan S, et al: Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. Liver Int 2011;31:740-743.
7. Inuzuka T, et al: Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: A case report. Oncology 2011;81(suppl 1):152-157.
8. Curtit E, et al: Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: A case report. J Clin Oncol 2011;29:e330-e332.
9. Wang SX, et al: Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: A case report. Target Oncol 2010;5:59-63.
10. Yeganeh M, et al: Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. Am J Transplant 2009;9:2851-2854.
11. Chelis L, et al: Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report. Med Oncol 2011;28(suppl 1):S165-S168.
12. Kudo M, Ueshima K: Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Oncology 2010;78(suppl 1):154-166.
13. Imai Y, et al: Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998;129:94-99.
14. Nakazawa T, et al: Rapid regression of advanced hepatocellular carcinoma associated with elevation of des-gamma-carboxy prothrombin after short-term treatment with sorafenib - a report of two cases. Case Rep Oncol 2010;3:298-303.